A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Latest Information Update: 29 May 2025
At a glance
- Drugs Leuprorelin (Primary) ; Rezvilutamide (Primary) ; SHR-A1921 (Primary) ; Trastuzumab rezetecan (Primary)
- Indications Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
Most Recent Events
- 23 May 2025 Planned End Date changed from 30 Sep 2026 to 30 Dec 2026.
- 23 May 2025 Planned primary completion date changed from 30 Sep 2025 to 30 Dec 2025.
- 04 Jun 2024 Results (n=21) of preliminary safety analysis of molecular subtype-guided precision therapy for advanced salivary gland cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology